Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich’s Combo™ Bio-engineered Sirolimus Eluting Stent

September 24, 2010 By Bio-Medicine.Org

WASHINGTON, Sept. 24 /PRNewswire/ — OrbusNeich today announced
at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in
Washington the completion of patient enrollment in the randomized
clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent
(Combo Stent) with 183 patients included at sites in Asia,
Australia, Europe and South America.

“Completion of enrollment of this study represents a significant
milestone as we look to validate the potential for the Combo Stent
in a clinical setting,” said Al Novak, Chairman and CEO of
OrbusNeich.

The primary objective of the prospective, randomized,
multicenter study, called REMEDEE (Randomized
Evaluation of an abluMinal sirolimus
coatED bio-Engineered
stEnt), is to demonstrate safety and effectiveness of
the Combo Stent compared to the TAXUS® Liberte®
paclitaxel-eluting stent in patients with symptomatic, ischemic
heart disease due to a stenotic lesion located in a native coronary
artery. This objective will be measured in patients by a comparison
of in-stent late lumen loss at nine months post-procedure.

Michael Haude, M.D., director of Medical Clinic I at the
Lukaskrankenhaus in Neuss, Germany, and one of the trial’s
principal investigators, added, “The Combo Stent has the potential
to bring a unique treatment option to physicians by combining the
proven Genous endothelial progenitor cell capture technology with a
low dose sirolimus elution. Because the pre-clinical data
demonstrate lower neointimal hyperplasia and improved endothelial
coverage, we look forward to obtaining clinical confirmation of the
results.”

Secondary endpoints include all-cause and cardiac mortality,
myocardial infarction, Major Adverse Cardiac Event (MACE) and stent
thrombosis rates at 30 days, nine months and one through five
years, as well as clinically driven Target Lesion Revascularization
(TLR), Target Ves

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech